aibioModerna sells $3.0 billion of zero-coupon convertible notes after upsized pricing
Tickers MRNA
The notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business.
Key facts
- Company
- Moderna, Inc. (NASDAQ: MRNA)
- News type
- Debt Financing
- Primary source
- Moderna (SEC Form 8-K)
Moderna priced $2.6 billion of convertible senior notes due 2032, upsized from $2.0 billion, the company said on August 28, 2026. The notes pay no regular interest and convert at about $210.58 per share.
That conversion price is about 47.5% above Moderna's closing price of $142.77 on August 27, according to the pricing release. Moderna expected net proceeds of about $2,562.9 million, or about $2,957.3 million if buyers took up an option for $400 million more.
The details
The notes are senior unsecured obligations that mature on March 1, 2032. On conversion, Moderna can pay in cash, shares or a mix. It cannot redeem the notes before September 6, 2029, and after that only if its share price has been at least 130% of the conversion price for a set period, per the release.
Buyers then took the full $400 million option, which brought the total to $3.0 billion and net proceeds to about $2,957.3 million, according to the 8-K. Moderna spent $328.8 million of the proceeds on capped call transactions meant to offset dilution, up from about $285 million at pricing. The cap price is $392.6175 per share, 175% above the August 27 closing price. Based on the initial conversion rate and the full $3.0 billion size, the notes convert into 14,246,100 shares, and up to 21,012,600 shares in limited cases, according to the 8-K filed on September 1.
The company said it would use the money for general corporate purposes, "which may include the flexibility to invest in the growth of our oncology business and repayment of debt," per its launch announcement on August 27.
Context
The sale came nine days after Merck and Moderna said the phase 3 INTerpath-001 trial of the cancer therapy intismeran autogene met its primary endpoint in melanoma. Moderna's balance sheet had been shrinking. Cash and investments were $6.9 billion at June 30, down from $7.5 billion at March 31, and the company paid $950 million in July for a litigation settlement, per the Q2 report.
The 10-Q says the settlement was with Arbutus and Genevant. Moderna also has a $1.5 billion secured term loan facility led by Ares Capital, with $600 million funded at closing in November 2025 and $900 million available in delayed draws. In July, the company projected 2026 year-end cash of $4.7 billion to $5.2 billion before any more loan draws, per its results.
What it means for investors
The deal gives Moderna several billion dollars at no cash interest cost, at a time when its sales are small and seasonal. Second quarter revenue was only $145 million. The trade-off is potential dilution of up to about 14 million shares at conversion, softened by the capped call up to $392.62 a share.
Timing matters. Moderna sold the notes nine days after the phase 3 readout and set a conversion price 47.5% above the August 27 close. Moderna's only long-term debt at June 30 was $591 million, the funded part of the secured Ares loan.
The risk is that Moderna still burns cash quickly. It lost $2.1 billion in the first half of 2026. The new money buys time to launch intismeran, if approved, but the company needs revenue growth to stop drawing down reserves.
What to watch
The INTerpath-001 data are scheduled for the ESMO Congress, October 23 to 27. Moderna's Analyst Day is November 12, per the company.